GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading GWPH News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-1.06%10.759.9%$288.61m
PRGOPerrigo Co. Plc
-0.29%67.964.8%$175.25m
SHPGShire PLC Sponsored ADR
0.70%175.230.3%$161.02m
MDCOMedicines Company
1.40%50.6922.6%$131.53m
ENDPEndo International Plc
-0.20%9.978.9%$127.59m
JAZZJazz Pharmaceuticals Plc
0.45%143.141.9%$87.29m
MNKMallinckrodt Plc
-0.21%43.0912.8%$86.16m
UTHRUnited Therapeutics Corporation
0.66%140.0511.5%$84.42m
PRXLPAREXEL International Corporation
0.86%62.356.7%$69.81m
PCRXPacira Pharmaceuticals, Inc.
-0.11%46.9016.9%$64.97m
PTLAPortola Pharmaceuticals, Inc.
0.55%38.4410.3%$48.16m
ICPTIntercept Pharmaceuticals, Inc.
0.80%116.7322.8%$46.26m
HZNPHorizon Pharma plc
-1.31%14.379.7%$45.60m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.04%121.179.9%$39.52m
ICLRICON Plc
1.73%78.942.8%$38.09m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.